← 返回

以靶向磷脂酰丝氨酸的小分子药物偶联物重振肝脏肿瘤微环境免疫

英文原题:Rejuvenating hepatic tumor microenvironment immunity with a phosphatidylserine-targeting small molecule drug conjugate.

查看英文原题

Rejuvenating hepatic tumor microenvironment immunity with a phosphatidylserine-targeting small molecule drug conjugate.

PubMed 2022/05/11(内容时间) Biomed Pharmacother

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

我们设计、合成并评估了一类靶向磷脂酰丝氨酸的锌(II)二吡啶胺药物偶联物,并发现偶联物16b可诱导免疫细胞浸润,将肝脏“冷”肿瘤微环境重塑为炎症性“热”微环境。研究通过连接子修饰开展构效关系分析,并进一步进行药代动力学评估,以提高偶联物在体内的溶解度和稳定性。在自发性肝细胞癌小鼠模型中,偶联物16b的抗肿瘤疗效优于索拉非尼。尤其观察到CD8阳性T细胞浸润和颗粒酶B水平显著增加,为使肿瘤摆脱其内在免疫抑制微环境提供了线索。对肿瘤炎症相关mRNA表达谱的评估显示,偶联物16b通过诱导STAT1、CXCL9、CCL5和PD-L1等关键基因表达,重塑了肿瘤微环境,增强T细胞、巨噬细胞、NK细胞、趋化因子及细胞因子的功能。本研究表明,靶向细胞凋亡的诊疗一体化药物可促进多类免疫细胞进入肿瘤,为联合免疫检查点阻断提供潜在治疗策略。

展开英文摘要原文

We report the design, synthesis and evaluation of a class of phosphatidylserine-targeting zinc (II) dipicolylamine drug conjugates and show that conjugate 16b elicits immune cell infiltration and remodels the "cold" hepatic tumor microenvironment to the inflamed "hot" tumor. Structure-property relationship study via linker modifications and subsequent pharmacokinetics profiling were carried out to improve the solubility and stability of the conjugates in vivo. In a spontaneous hepatocellular carcinoma mouse model, we showed that conjugate 16b exhibited better antitumor efficacy than sorafenib.

In particular, significant increase of CD8 + T cell infiltration and granzyme B level was observed, providing insights in sensitizing tumors from intrinsic immune suppressive microenvironment. Evaluation of tumor inflammation-related mRNA expression profile revealed that conjugate 16b, through inductions of key gene expressions including STAT1, CXCL9, CCL5, and PD-L1, rejuvenated tumor microenvironment with enhancement in T cell-, macrophage-, NK cell-, chemokines and cytokines'- functions.

Our study establishes that an apoptosis-targeting theranostic enables enrichment of multifaceted immune cells into the tumor mass, which provides potential therapeutic strategies in the combination with immune checkpoint blockade treatment.

论文信息

作者
Huang KH、Liu YT、Pan PY、Lo CF、Liu KL、Yeh TK、Huang LR、Tsou LK
第一作者单位
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan, ROC.Taiwan
通讯作者单位
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan, ROC. Electronic address: kelvintsou@nhri.edu.tw.Taiwan
期刊
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2022 Jul
原文标识
PubMed 35567985 · DOI 10.1016/j.biopha.2022.113084